Global Renin-Angiotensin-System (RAS)-Acting Agent market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

Global Renin-Angiotensin-System (RAS)-Acting Agent Market Trends, Growth and Outlook 2025-31

The global Renin-Angiotensin-System (RAS)-Acting Agent market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031. According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment. Infinity Market Research newest research report, the Renin-Angiotensin-System (RAS)-Acting Agent Industry Forecast looks at past sales and reviews total world Renin-Angiotensin-System (RAS)-Acting Agent sales in 2024, providing a comprehensive analysis by region and market sector of projected Renin-Angiotensin-System (RAS)-Acting Agent sales for 2025 through 2031. With Renin-Angiotensin-System (RAS)-Acting Agent sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Renin-Angiotensin-System (RAS)-Acting Agent industry. This Insight Report provides a comprehensive analysis of the global Renin-Angiotensin-System (RAS)-Acting Agent landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Renin-Angiotensin-System (RAS)-Acting Agent portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Renin-Angiotensin-System (RAS)-Acting Agent market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Renin-Angiotensin-System (RAS)-Acting Agent and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Renin-Angiotensin-System (RAS)-Acting Agent. This report presents a comprehensive overview, market shares, and growth opportunities of Renin-Angiotensin-System (RAS)-Acting Agent market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Angiotensin Converting Enzyme Inhibitors (ACEi) &nbsp;&nbsp;&nbsp; Angiotensin Receptor Blockers (ARBs) Segmentation by Application: &nbsp;&nbsp;&nbsp; Hypertension &nbsp;&nbsp;&nbsp; Heart Failure &nbsp;&nbsp;&nbsp; Chronic Kidney Disease &nbsp;&nbsp;&nbsp; Other This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Novartis AG &nbsp;&nbsp;&nbsp; Pfizer, Inc. &nbsp;&nbsp;&nbsp; AstraZeneca plc &nbsp;&nbsp;&nbsp; Merck & Co., Inc. &nbsp;&nbsp;&nbsp; Sanofi S.A. &nbsp;&nbsp;&nbsp; Bristol-Myers Squibb Company &nbsp;&nbsp;&nbsp; Daiichi Sankyo Company,Limited &nbsp;&nbsp;&nbsp; Takeda Pharmaceutical Company Limited &nbsp;&nbsp;&nbsp; Boehringer lngelheim GmbH &nbsp;&nbsp;&nbsp; Johnson & Johnson Key Questions Addressed in this Report What is the 10-year outlook for the global Renin-Angiotensin-System (RAS)-Acting Agent market? What factors are driving Renin-Angiotensin-System (RAS)-Acting Agent market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Renin-Angiotensin-System (RAS)-Acting Agent market opportunities vary by end market size? How does Renin-Angiotensin-System (RAS)-Acting Agent break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Annual Sales 2020-2031 &nbsp;2.1.2 World Current & Future Analysis for Renin-Angiotensin-System (RAS)-Acting Agent by Geographic Region, 2020, 2024 & 2031 &nbsp;2.1.3 World Current & Future Analysis for Renin-Angiotensin-System (RAS)-Acting Agent by Country/Region, 2020, 2024 & 2031 &nbsp;2.2 Renin-Angiotensin-System (RAS)-Acting Agent Segment by Type &nbsp;2.2.1 Angiotensin Converting Enzyme Inhibitors (ACEi) &nbsp;2.2.2 Angiotensin Receptor Blockers (ARBs) &nbsp;2.3 Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type &nbsp;2.3.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Type (2020-2025) &nbsp;2.3.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue and Market Share by Type (2020-2025) &nbsp;2.3.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Sale Price by Type (2020-2025) &nbsp;2.4 Renin-Angiotensin-System (RAS)-Acting Agent Segment by Application &nbsp;2.4.1 Hypertension &nbsp;2.4.2 Heart Failure &nbsp;2.4.3 Chronic Kidney Disease &nbsp;2.4.4 Other &nbsp;2.5 Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application &nbsp;2.5.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sale Market Share by Application (2020-2025) &nbsp;2.5.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue and Market Share by Application (2020-2025) &nbsp;2.5.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Sale Price by Application (2020-2025) 3 Global by Company &nbsp;3.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Breakdown Data by Company &nbsp;3.1.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Annual Sales by Company (2020-2025) &nbsp;3.1.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Company (2020-2025) &nbsp;3.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Annual Revenue by Company (2020-2025) &nbsp;3.2.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Company (2020-2025) &nbsp;3.2.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Company (2020-2025) &nbsp;3.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Sale Price by Company &nbsp;3.4 Key Manufacturers Renin-Angiotensin-System (RAS)-Acting Agent Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers Renin-Angiotensin-System (RAS)-Acting Agent Product Location Distribution &nbsp;3.4.2 Players Renin-Angiotensin-System (RAS)-Acting Agent Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for Renin-Angiotensin-System (RAS)-Acting Agent by Geographic Region &nbsp;4.1 World Historic Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Geographic Region (2020-2025) &nbsp;4.1.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Annual Sales by Geographic Region (2020-2025) &nbsp;4.1.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Annual Revenue by Geographic Region (2020-2025) &nbsp;4.2 World Historic Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Country/Region (2020-2025) &nbsp;4.2.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Annual Sales by Country/Region (2020-2025) &nbsp;4.2.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Renin-Angiotensin-System (RAS)-Acting Agent Sales Growth &nbsp;4.4 APAC Renin-Angiotensin-System (RAS)-Acting Agent Sales Growth &nbsp;4.5 Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Growth &nbsp;4.6 Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales Growth 5 Americas &nbsp;5.1 Americas Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country &nbsp;5.1.1 Americas Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2020-2025) &nbsp;5.1.2 Americas Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Country (2020-2025) &nbsp;5.2 Americas Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2020-2025) &nbsp;5.3 Americas Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region &nbsp;6.1.1 APAC Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region (2020-2025) &nbsp;6.1.2 APAC Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Region (2020-2025) &nbsp;6.2 APAC Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2020-2025) &nbsp;6.3 APAC Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe Renin-Angiotensin-System (RAS)-Acting Agent by Country &nbsp;7.1.1 Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2020-2025) &nbsp;7.1.2 Europe Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Country (2020-2025) &nbsp;7.2 Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2020-2025) &nbsp;7.3 Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent by Country &nbsp;8.1.1 Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2020-2025) &nbsp;8.1.2 Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Country (2020-2025) &nbsp;8.2 Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2020-2025) &nbsp;8.3 Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of Renin-Angiotensin-System (RAS)-Acting Agent &nbsp;10.3 Manufacturing Process Analysis of Renin-Angiotensin-System (RAS)-Acting Agent &nbsp;10.4 Industry Chain Structure of Renin-Angiotensin-System (RAS)-Acting Agent 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 Renin-Angiotensin-System (RAS)-Acting Agent Distributors &nbsp;11.3 Renin-Angiotensin-System (RAS)-Acting Agent Customer 12 World Forecast Review for Renin-Angiotensin-System (RAS)-Acting Agent by Geographic Region &nbsp;12.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Size Forecast by Region &nbsp;12.1.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Forecast by Region (2026-2031) &nbsp;12.1.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Annual Revenue Forecast by Region (2026-2031) &nbsp;12.2 Americas Forecast by Country (2026-2031) &nbsp;12.3 APAC Forecast by Region (2026-2031) &nbsp;12.4 Europe Forecast by Country (2026-2031) &nbsp;12.5 Middle East & Africa Forecast by Country (2026-2031) &nbsp;12.6 Global Renin-Angiotensin-System (RAS)-Acting Agent Forecast by Type (2026-2031) &nbsp;12.7 Global Renin-Angiotensin-System (RAS)-Acting Agent Forecast by Application (2026-2031) 13 Key Players Analysis &nbsp;13.1 Novartis AG &nbsp;13.1.1 Novartis AG Company Information &nbsp;13.1.2 Novartis AG Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications &nbsp;13.1.3 Novartis AG Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.1.4 Novartis AG Main Business Overview &nbsp;13.1.5 Novartis AG Latest Developments &nbsp;13.2 Pfizer, Inc. &nbsp;13.2.1 Pfizer, Inc. Company Information &nbsp;13.2.2 Pfizer, Inc. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications &nbsp;13.2.3 Pfizer, Inc. Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.2.4 Pfizer, Inc. Main Business Overview &nbsp;13.2.5 Pfizer, Inc. Latest Developments &nbsp;13.3 AstraZeneca plc &nbsp;13.3.1 AstraZeneca plc Company Information &nbsp;13.3.2 AstraZeneca plc Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications &nbsp;13.3.3 AstraZeneca plc Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.3.4 AstraZeneca plc Main Business Overview &nbsp;13.3.5 AstraZeneca plc Latest Developments &nbsp;13.4 Merck & Co., Inc. &nbsp;13.4.1 Merck & Co., Inc. Company Information &nbsp;13.4.2 Merck & Co., Inc. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications &nbsp;13.4.3 Merck & Co., Inc. Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.4.4 Merck & Co., Inc. Main Business Overview &nbsp;13.4.5 Merck & Co., Inc. Latest Developments &nbsp;13.5 Sanofi S.A. &nbsp;13.5.1 Sanofi S.A. Company Information &nbsp;13.5.2 Sanofi S.A. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications &nbsp;13.5.3 Sanofi S.A. Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.5.4 Sanofi S.A. Main Business Overview &nbsp;13.5.5 Sanofi S.A. Latest Developments &nbsp;13.6 Bristol-Myers Squibb Company &nbsp;13.6.1 Bristol-Myers Squibb Company Company Information &nbsp;13.6.2 Bristol-Myers Squibb Company Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications &nbsp;13.6.3 Bristol-Myers Squibb Company Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.6.4 Bristol-Myers Squibb Company Main Business Overview &nbsp;13.6.5 Bristol-Myers Squibb Company Latest Developments &nbsp;13.7 Daiichi Sankyo Company,Limited &nbsp;13.7.1 Daiichi Sankyo Company,Limited Company Information &nbsp;13.7.2 Daiichi Sankyo Company,Limited Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications &nbsp;13.7.3 Daiichi Sankyo Company,Limited Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.7.4 Daiichi Sankyo Company,Limited Main Business Overview &nbsp;13.7.5 Daiichi Sankyo Company,Limited Latest Developments &nbsp;13.8 Takeda Pharmaceutical Company Limited &nbsp;13.8.1 Takeda Pharmaceutical Company Limited Company Information &nbsp;13.8.2 Takeda Pharmaceutical Company Limited Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications &nbsp;13.8.3 Takeda Pharmaceutical Company Limited Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.8.4 Takeda Pharmaceutical Company Limited Main Business Overview &nbsp;13.8.5 Takeda Pharmaceutical Company Limited Latest Developments &nbsp;13.9 Boehringer lngelheim GmbH &nbsp;13.9.1 Boehringer lngelheim GmbH Company Information &nbsp;13.9.2 Boehringer lngelheim GmbH Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications &nbsp;13.9.3 Boehringer lngelheim GmbH Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.9.4 Boehringer lngelheim GmbH Main Business Overview &nbsp;13.9.5 Boehringer lngelheim GmbH Latest Developments &nbsp;13.10 Johnson & Johnson &nbsp;13.10.1 Johnson & Johnson Company Information &nbsp;13.10.2 Johnson & Johnson Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications &nbsp;13.10.3 Johnson & Johnson Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.10.4 Johnson & Johnson Main Business Overview &nbsp;13.10.5 Johnson & Johnson Latest Developments 14 Research Findings and Conclusion

Report	Global Renin-Angiotensin-System (RAS)-Acting Agent Market Growth 2025-2031
Selected License	Multi ID: LPI38776

Buyer Information

Order Summary